Literature DB >> 3867660

Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis.

J Modai, D Vittecoq, J M Decazes, A Meulemans.   

Abstract

The penetration of imipenem and cilastatin into the cerebrospinal fluid (CSF) was determined in patients with bacterial meningitis. Four 1000 mg doses [corrected] of both imipenem and cilastatin were infused intravenously over 20-30 min at 6 h intervals, first between days 2 and 4, and again, whenever possible, between days 11 to 20, in 12 patients with bacterial meningitis undergoing treatment with other antibiotics. Concentrations of imipenem and cilastatin in serum and cerebrospinal fluid samples obtained either at 60, 90 or 120 min following the fourth dose were measured by high pressure liquid chromatography. Concentrations of imipenem in CSF ranged from 0.5 to 11 mg/1 and concentrations of cilastatin ranged from 1.1 to 10.5 mg/1, depending on the sampling time and the time elapsed since the onset of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3867660     DOI: 10.1093/jac/16.6.751

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.

Authors:  A Dupuis; W Couet; J Paquereau; S Debarre; A Portron; C Jamois; S Bouquet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Treatment of a meningitis due to an Enterobacter aerogenes producing a derepressed cephalosporinase and a Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Authors:  C de Champs; D Guelon; D Joyon; D Sirot; M Chanal; J Sirot
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

4.  Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.

Authors:  F Fitoussi; C Doit; K Benali; S Bonacorsi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  NLM's practices for handling errata and retractions.

Authors:  S Kotzin; P L Schuyler
Journal:  Bull Med Libr Assoc       Date:  1989-10

6.  Determination of imipenem and cilastatin in serum and tissue by high-pressure liquid chromatography.

Authors:  R Krausse; U Ullmann
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

7.  Complement-derived polypeptide C3adesArg as a mediator of inflammation at the blood-brain barrier in a new experimental cat model.

Authors:  H G Höllerhage; G F Walter; D Stolke
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

8.  Imipenem therapy of brain abscesses.

Authors:  V Asensi; J A Carton; J A Maradona; J M Asensi; F Pérez; P Redondo; A López; J M Arribas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

9.  Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae.

Authors:  J H Jorgensen; J M Swenson; F C Tenover; M J Ferraro; J A Hindler; P R Murray
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

Review 10.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.